TCBIO Texas Capital Bancshares Forecast, Technical & Fundamental Analysis

TCBIO in downward trend: price dove below 50-day moving average on August 11, 2025

TCBIO moved below its 50-day moving average on August 11, 2025 date and that indicates a change from an upward trend to a downward trend. In of 45 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for TCBIO turned negative on August 12, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 10-day moving average for TCBIO crossed bearishly below the 50-day moving average on August 01, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for TCBIO entered a downward trend on August 15, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Momentum Indicator moved above the 0 level on August 15, 2025. You may want to consider a long position or call options on TCBIO as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TCBIO advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .

TCBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TCBIO's P/B Ratio (0.000) is slightly lower than the industry average of (1.101). P/E Ratio (0.000) is within average values for comparable stocks, (19.541). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.598). TCBIO has a moderately high Dividend Yield (0.070) as compared to the industry average of (0.037). P/S Ratio (0.000) is also within normal values, averaging (5.074).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. TCBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 54, placing this stock worse than average.